Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10307810 | 0.85 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2HDAC1HDAC2MAPT | |
| SCHEMBL3101921 | 0.79 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2HDAC1HDAC2MAPT | |
| SCHEMBL17256326 | 0.78 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2HDAC1HDAC2MAPT | |
| SCHEMBL16387329 | 0.78 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2HDAC1HDAC2MAPT | |
| SCHEMBL14921878 | 0.78 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2HDAC1HDAC2MAPT | |
| SCHEMBL31005435 | 0.78 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2HDAC1HDAC2MAPT | |
| SCHEMBL123215 | 0.77 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2HDAC1HDAC2MAPT | |
| Hydrochloric Acid SCHEMBL16539188 | 0.76 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2HDAC1HDAC2MAPT | |
| SCHEMBL98030 | 0.76 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HDAC1HDAC2MAPT | |
| SCHEMBL29811281 | 0.76 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HDAC1HDAC2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150445-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | SHORR ROBERT G L (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150445-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | SHORR ROBERT G L (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150445-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | SLC25A1, SLC25A21, SLC25A11 | ALDH1A1 783/4885SMN1; SMN2 1524/4885HDAC1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.